Clinical Trial Update: Eltrombopag for Moderate Aplastic Anemia [Phase 2]

View source ↗

Summary

This document summarizes Phase 2 results from a trial of eltrombopag in moderate aplastic anemia, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aplastic Anemia
• Bone Marrow Failure Disorders

Drugs mentioned

• Promacta (eltrombopag)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Moderate Aplastic Anemia, Unilineage Bone Marrow Failure Disorders | Phase 2 | Status: COMPLETED | Results posted: 2019-04-23